Case W. McNamara

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

The paper identifies and optimizes imidazothiazole carboxamides as anti-tuberculosis agents, showing activity against drug-resistant strains and improved potency in analogs.

The paper identifies a novel Rv1625c agonist chemotype with antitubercular activity, optimizing its structure to improve potency and bioavailability.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

The paper identifies three new cyclic depsipeptides from a marine cyanobacterium using AI tools and metabolomics, showing their antiplasmodial activity and structural diversity.

The paper identifies 44 compounds with >50% inhibitory effects against Toxoplasma gondii bradyzoites using a high-throughput screen and characterizes one compound's activity.

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

This paper identifies mCMQ069, a novel antimalarial with potential for single-dose cure and one-month chemoprevention, showing improved pharmacokinetic properties over KAF156.

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.

The paper identifies genetic determinants of chemical resistance in yeast using in vitro evolution and whole genome sequencing, revealing key transcription factors involved in drug resistance.